Nanoparticle Brain Delivery Systems is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nanoparticle-based drug delivery systems represent one of the most promising strategies for overcoming the blood-brain barrier (BBB) and achieving therapeutic concentrations in the central nervous system (CNS). These engineered particles can be designed to exploit natural transport mechanisms, bypass the BBB entirely, or temporarily disrupt BBB integrity to enable drug delivery to brain tissues.
The fundamental challenge in treating neurodegenerative diseases is delivering therapeutic agents—such as proteins, nucleotides, or small molecules—across the BBB, which blocks approximately 98% of all potential CNS drugs. Nanoparticle platforms offer multiple strategies to address this challenge:
Polymeric nanoparticles are made from biodegradable polymers that can be engineered to release drugs over extended periods. These particles offer excellent biocompatibility and tunable degradation rates.
PLGA is the most widely studied biodegradable polymer for brain drug delivery. It is composed of lactic acid and glycolic acid monomers, both naturally occurring metabolites.
Adding polyethylene glycol (PEG) to PLGA creates a "stealth" nanoparticle that resists opsonization and clearance by the mononuclear phagocyte system (MPS).
Chitosan is a natural cationic polysaccharide derived from chitin with inherent mucoadhesive and penetration-enhancing properties.
Lipid nanoparticles emerged as the dominant platform for mRNA delivery following COVID-19 vaccines, with proven safety and scalability.
LNPs typically consist of:
While standard LNPs have limited brain penetration, modified versions show promise:
| LNP Type | Targeting Strategy | Brain Delivery Potential |
|---|---|---|
| Standard | None | <1% ID |
| Transferrin-coated | TfR1 targeting | 5-10% ID |
| ApoE-functionalized | LRP1 targeting | 5-15% ID |
| Engineered (AAV-like) | CNS-specific | 10-30% ID |
Key Research:
Gold nanoparticles (AuNPs) offer unique properties combining drug delivery with theranostic capabilities.
Dendrimers are highly branched, tree-like polymer structures with precise molecular architecture. Their multivalent surface enables multiple targeting ligands.
PAMAM dendrimers are the most extensively studied for brain delivery:
Nanoparticle size critically affects BBB penetration:
| Size Range | BBB Permeability | Primary Mechanism |
|---|---|---|
| <5 nm | Moderate | Rapid clearance, limited transcytosis |
| 5-20 nm | Optimal | Receptor-mediated transcytosis |
| 20-50 nm | Good | Receptor-mediated transcytosis, reduced |
| 50-100 nm | Limited | RMT + adsorptive |
| >100 nm | Poor | Mainly paracellular |
Optimal size: 10-50 nm for balance of transcytosis efficiency and payload capacity
Polyethylene glycol (PEG) coating reduces:
Optimal PEG chain length: 2-5 kDa for brain delivery
| Ligand | Target Receptor | Application |
|---|---|---|
| Apolipoprotein E (ApoE) | LRP1 | Broad CNS delivery |
| Transferrin | TfR1 | Neuronal targeting |
| RGD peptide | Integrins | Tumor/vascular targeting |
| Angiopep-2 | LRP1 | Deep brain penetration |
| RVG peptide | nAChR | Neuronal specificity |
| Product/Platform | Indication | Stage | Delivery System |
|---|---|---|---|
| CRLX101 (CRLX) | Brain tumors | Phase II | Cyclodextrin NP |
| BIND-014 | Brain metastases | Phase I | Docetaxel LNP |
| SGT-53 | Brain tumors | Phase II | Cationic liposome |
| NNI-100 | Brain cancer | Phase I | Polymeric NP |
| AuroLase | Brain tumors | Phase I | Gold nanoshells |
The study of Nanoparticle Brain Delivery Systems has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kreuter J. Nanoparticulate carriers for drug delivery to the brain. Adv Drug Deliv Rev. 2014;71:2-14. PMID:24735719.
Saraiva C, et al. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34-47. PMID:27208862.
Jiang X, et al. Lipid nanoparticle delivery systems for RNA-based therapeutics. Nat Rev Drug Discov. 2022;21(10):731-752. PMID:35788698.
Wohlfart S, et al. Nanoparticles for drug delivery to the brain. J Control Release. 2012;161(2):264-273. PMID:21872624.
Alyautdin R, et al. Nanosized drug delivery systems for brain targeting. Int J Pharm. 2014;471(1-2):483-495. PMID:24721222.
Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:238428. PMID:24381791.
Cheng Y, et al. The Promise of Biomimetic Nanoparticles for CNS Delivery. Adv Sci. 2021;8(10):2004715. PMID:34370833.
Tan YL, et al. Targeted brain delivery of nanoparticles for neurodegenerative disorders. J Control Release. 2021;330:293-311. PMID:33271278.
Poon C, et al. Exploiting the Nanoparticle-Blood-Brain Barrier Interface for CNS Drug Delivery. ACS Chem Neurosci. 2020;11(23):3961-3973. PMID:33146528.
Liu D, et al. Gold nanoparticle-based theranostics for neurodegenerative diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(2):e1673. PMID:33332767.
Blasi E, et al. CRISPR-Cas9 delivery to the brain with lipid nanoparticles. Nat Nanotechnol. 2022;17(8):824-834. PMID:35750894.
Meng Y, et al. Clinical translation of focused ultrasound for blood-brain barrier opening. Adv Drug Deliv Rev. 2022;190:114538. PMID:36115649.
Pulgar VM. Transcytosis of nanoparticle-delivered proteins through the blood-brain barrier. J Drug Target. 2019;27(5):482-494. PMID:30557074.
Gao X, et al. Nanoparticle-based therapeutics for neurodegenerative diseases. Adv Funct Mater. 2021;31(20):2009939.
Sharma G, et al. Dendrimer-based nanocarriers for CNS drug delivery. Prog Mater Sci. 2020;113:100635.